IONS
HEALTHCAREIonis Pharmaceuticals Inc
$76.85+1.60 (+2.13%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IONS Today?
No stock-specific AI insight has been generated for IONS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$32.00$86.74
$76.85
Fundamentals
Market Cap$12.7B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding165.3M
IONS News
24 articles- Tweedy Browne's Strategic Moves: Ionis Pharmaceuticals Inc. Sees Significant ReductionYahoo Finance·May 6, 2026
- Ionis to host 2026 virtual Annual Meeting of StockholdersYahoo Finance·May 4, 2026
- Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsYahoo Finance·May 1, 2026
- Ionis to present at upcoming investor conferencesYahoo Finance·May 1, 2026
- Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%Yahoo Finance·Apr 30, 2026
- IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 ViewYahoo Finance·Apr 30, 2026
- Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 29, 2026
- Ionis Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Ionis (IONS) Q1 2026 Earnings Call TranscriptMotley Fool·Apr 29, 2026
- Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key MetricsYahoo Finance·Apr 29, 2026
- Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 29, 2026
- Ionis reports first quarter 2026 financial results and highlights progress on key programsYahoo Finance·Apr 29, 2026
- Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis BYahoo Finance·Apr 28, 2026
- Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.Yahoo Finance·Apr 27, 2026
- A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Recent PullbackYahoo Finance·Apr 26, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.Yahoo Finance·Apr 21, 2026
- Ionis (IONS) Q4 2025 Earnings TranscriptMotley Fool·Apr 21, 2026
- Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual MeetingYahoo Finance·Apr 21, 2026
- How The Ionis Pharmaceuticals (IONS) Story Is Shifting With New Targets And 2026 CatalystsYahoo Finance·Apr 20, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyGlobeNewswire Inc.·Apr 6, 2026
- Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger MarketBenzinga·Mar 26, 2026
- When Insider Selling Is a Good Thing: 2 Stocks to WatchInvesting.com·Mar 24, 2026
All 24 articles loaded
Price Data
Open$75.62
Previous Close$75.25
Day High$77.42
Day Low$75.29
52 Week High$86.74
52 Week Low$32.00
52-Week Range
$32.00$86.74
$76.85
Fundamentals
Market Cap$12.7B
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding165.3M
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—